Management of psoriasis as a systemic disease: what is the evidence?
NJ Korman - British Journal of Dermatology, 2020 - academic.oup.com
Background Psoriasis is a chronic, systemic immune‐mediated disease characterized by
development of erythematous, indurated, scaly, pruritic and often painful skin plaques …
development of erythematous, indurated, scaly, pruritic and often painful skin plaques …
Dendritic cells and macrophages in the pathogenesis of psoriasis
M Kamata, Y Tada - Frontiers in immunology, 2022 - frontiersin.org
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema.
This disease impairs patients' quality of life enormously. Pathological findings demonstrate …
This disease impairs patients' quality of life enormously. Pathological findings demonstrate …
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
Background The multimorbid burden and use of systemic immunosuppressants in people
with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 …
with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 …
Microneedles for painless transdermal immunotherapeutic applications
Immunotherapy has recently garnered plenty of attention to improve the clinical outcomes in
the treatment of various diseases. However, owing to the dynamic nature of the immune …
the treatment of various diseases. However, owing to the dynamic nature of the immune …
Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis
Abstract Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine
signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 …
signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 …
Current concepts of psoriasis immunopathogenesis
Psoriasis is a recurrent, chronic, immune-mediated, systemic inflammatory disease of the
skin, joints, and other organic systems. After atopic dermatitis, chronic stationary psoriasis is …
skin, joints, and other organic systems. After atopic dermatitis, chronic stationary psoriasis is …
Metabolic syndrome and psoriasis: mechanisms and future directions
Y Hao, Y Zhu, S Zou, P Zhou, Y Hu, Q Zhao… - Frontiers in …, 2021 - frontiersin.org
Psoriasis is an immune-mediated systemic disease with associated comorbidities, including
metabolic syndrome (MetS) which contributes substantially to premature mortality in patients …
metabolic syndrome (MetS) which contributes substantially to premature mortality in patients …
Old and new biological therapies for psoriasis
K Rønholt, L Iversen - International journal of molecular sciences, 2017 - mdpi.com
Biological therapy became available for psoriasis with the introduction of alefacept at the
beginning of this century. Up to then, systemic treatment options comprised small molecule …
beginning of this century. Up to then, systemic treatment options comprised small molecule …
[HTML][HTML] Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
JG Krueger, IB McInnes, A Blauvelt - Journal of the American Academy of …, 2022 - Elsevier
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease.
The Janus kinase-signal transducer and activator of transcription pathway plays a major role …
The Janus kinase-signal transducer and activator of transcription pathway plays a major role …